Advertisement

Parkinsonmittel

  • Ulrich Schwabe

Zusammenfassung

Levodopapräparate sind die führenden Vertreter der Parkinsonmittel. Ihre Verordnungen sind 2015 erneut leicht angestiegen und umfassen 41% des Verordnungsvolumens. An zweiter Stelle folgen die Dopaminrezeptoragonisten mit Konzentration auf Pramipexol. COMT-Hemmer und MAO-B-Hemmer werden in geringeren Umfang verordnet. Die Verordnungen von Anticholinergika und Amantadin stagnieren auf niedrigem Niveau.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ahlskog JE, Uitti RJ (2010): Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? Neurology 74: 1143–1148CrossRefPubMedPubMedCentralGoogle Scholar
  2. Birkmayer W, Hornykiewicz O (1961): Der L-Dioxyphenylalanin (L-DOPA) Effekt bei der Parkinson-Akinese. Wien klin Wschr. 78: 787–788Google Scholar
  3. Chen JJ, Swope DM (2005): Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. J Clin Pharmacol 45: 878–894CrossRefPubMedGoogle Scholar
  4. Crosby NJ, Deane KH, Clarke CE (2003): Amantadine in Parkinson’s disease. Cochrane Database Syst Rev. 2003;(1):CD003468Google Scholar
  5. Deane KH, Spieker S, Clarke CE (2004): Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson’s disease. Cochrane Database Syst Rev. 2004 Oct 18;(4): CD004554Google Scholar
  6. Deutsche Gesellschaft für Neurologie (2012): Parkinson-Syndrome—Diagnostik und Therapie. Internet: http://www.dgn.org/leitlinien-online-2012/inhalte-nachkapitel/2346-ll-09-2012-parkinson-syndrome-diagnostikund-therapie.html
  7. European Medicines Agency (EMA) (2004): EMEA public statement on the lifting of the suspension of the marketing authorisation for tolcapone (Tasmar). Internet: http://www.emea.eu.int/pdfs/human/press/pus/1185404en.pdf
  8. Fahn S and the Parkinson Study Group (2005): Does levodopa slow or hasten the rate of progression of Parkinson’s disease? J Neurol 252 (Suppl 4): IV37–IV42Google Scholar
  9. Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH; SP513 investigators (2007): Rotigotine transdermal patch in early Parkinson’s disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 22: 2398–2404Google Scholar
  10. Huntington Study Group (2006): Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 66: 366–372CrossRefGoogle Scholar
  11. Kalia LV, Lang AE (2015): Parkinson’s disease. Lancet 386: 896–912CrossRefPubMedGoogle Scholar
  12. Katzenschlager R, Sampaio C, Costa J, Lees A (2003): Anticholinergics for symptomatic management of Parkinson’s disease. Cochrane Database Syst Rev. 2003;(2):CD003735Google Scholar
  13. Lees AJ (1995): Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson’s disease. Parkinson’s Disease Research Group of the United Kingdom. BMJ 311: 1602–1607CrossRefPubMedPubMedCentralGoogle Scholar
  14. Lees AJ, Hardy J, Revesz T (2009): Parkinson’s disease. Lancet 373: 2055–2066CrossRefPubMedGoogle Scholar
  15. Lees AJ, Katzenschlager R, Head J, Ben-Shlomo Y (2001): Tenyear follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology 57: 1687–1694CrossRefPubMedGoogle Scholar
  16. Müller-Vahl KR (2007): Die Benzamide Tiaprid, Sulpirid und Amisulprid in der Therapie des Tourette-Syndroms. Eine Standortbestimmung. Nervenarzt 78: 264–271CrossRefPubMedGoogle Scholar
  17. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E; ADAGIO Study Investigators (2009): A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 361: 1268–1278CrossRefPubMedGoogle Scholar
  18. Ossig C, Reichmann H (2013): Treatment of Parkinson’s disease in the advanced stage. J Neural Transm 120: 523–529CrossRefPubMedPubMedCentralGoogle Scholar
  19. Pålhagen SE, Dizdar N, Hauge T, Holmberg B, Jansson R, Linder J, Nyholm D, Sydow O, Wainwright M, Widner H, Johansson A (2012): Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease. Acta Neurol Scand 126: e29–33CrossRefPubMedGoogle Scholar
  20. Parkinson Study Group (2004): A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61: 561–566CrossRefGoogle Scholar
  21. Parkinson Study Group (2005): A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62: 241–248CrossRefGoogle Scholar
  22. Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, Rupp M, Boroojerdi B; SP 515 Investigators (2007): Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 6: 513–520Google Scholar
  23. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE for The 056 Study Group (2000): A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa.N Engl J Med 342: 1484–1491Google Scholar
  24. Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E; LARGO study group (2005): Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365: 947–954CrossRefPubMedGoogle Scholar
  25. Rascol O, Lozano A, Stern M, Poewe W (2011): Milestones in Parkinson’s disease therapeutics. Mov Disord 26: 1072–1082CrossRefPubMedGoogle Scholar
  26. Schapira AH (2004): Restless legs syndrome: an update on treatment options. Drugs 64: 149–158CrossRefPubMedGoogle Scholar
  27. Silver DE, Ruggieri S (1998): Initiating therapy for Parkinson’s disease. Neurology 50 (Suppl 6): S18–S22; discussion S44–S48CrossRefPubMedGoogle Scholar
  28. Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW (2010): Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 68: 18–27CrossRefPubMedGoogle Scholar
  29. The Parkinson Study Group (2004): Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61: 1044–1053Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Ulrich Schwabe
    • 1
  1. 1.Pharmakologisches InstitutUniversität HeidelbergHeidelberg

Personalised recommendations